SLC6A3 and attention deficit-hyperactivity disorder: A small randomized crossover trial in children with Attention-deficit/hyperactivity disorder (ADHD) found that genetic variation in the dopamine transporter (DAT1) was not associated with baseline differences in SICI or ICF, but DAT1 genotype influenced the effect of stimulant administration on these measures [72].